Immune-Checkpoint Inhibition for Metastatic Triple-Negative Breast Cancer: Safety First?
Last Updated: Wednesday, May 4, 2022
                        
            The approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges in the management of adverse events. In this article discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.
Advertisement
         
        News & Literature Highlights 
        
            
                    
        
    
    
        
 
    